We are live on ! Find out more
CALT

Calliditas Therapeutics AB American Depositary Shares
CALT

Delisted

CALT was delisted on the 20th of September, 2024.

Back to rankings

0 hedge funds and large institutions have $0 invested in Calliditas Therapeutics AB American Depositary Shares in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 5 → 0 (-5)

100% less capital inflows, than outflows

Capital inflows: $0 | Capital outflows: $750K

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 5

Holders
–
Holders Change
-5
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Crossmark Global Holdings
Crossmark Global Holdings
Texas
-$655K
2
Advisors Preferred
Advisors Preferred
Maryland
-$81.5K
3
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
-$12.2K
4
Missouri Trust & Investment Company
Missouri Trust & Investment Company
Missouri
-$1.4K

CALT Hedge Fund Activity: Q4 2024 in Review

0 of the 7,622 institutional investors tracked by Wall St. Rank reported a position in Calliditas Therapeutics AB American Depositary Shares (CALT) for Q4 2024, worth a combined $0 — down 100% from $750K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of CALT and 0 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Crossmark Global Holdings, exiting entirely with an estimated $655K sold.

  • 0 institutional investors held Calliditas Therapeutics AB American Depositary Shares (CALT) as of Q4 2024, down from 5 in Q3 2024.
  • Funds reported $0 of Calliditas Therapeutics AB American Depositary Shares stock for Q4 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Calliditas Therapeutics AB American Depositary Shares positions in Q4 2024 and 5 closed out, a net change of -5 holders.
  • The largest Calliditas Therapeutics AB American Depositary Shares seller in Q4 2024 was Crossmark Global Holdings, an estimated $655K sold.

Based on aggregated 13F filings for Q4 2024.